AstraZeneca executives at earnings conference, February 2020 (Natalie Grover for Endpoints News)

February 14, 2020 07:18 AM ESTUpdated February 21, 05:38 PM

Coronavirus outbreak clouds AstraZeneca's Q4 results and 2020 outlook

Natalie Grover

Reporter

LONDON — With nearly a fifth of total sales coming from China, AstraZeneca counts the coronavirus-hit nation as one of its biggest growth drivers. The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Coronavirus outbreak clouds AstraZeneca's Q4 results and 2020 outlook

Natalie Grover

Reporter

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Bristol Myers sues the federal government over 340B, following other drugmakers

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Coro­n­avirus out­break clouds As­traZeneca's Q4 re­sults and 2020 out­look

Natalie Grover

Reporter

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Coronavirus outbreak clouds AstraZeneca's Q4 results and 2020 outlook

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Bristol Myers sues the federal government over 340B, following other drugmakers

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy